Core Insights - Certara, Inc. has appointed Jon Resnick as the new CEO effective January 1, 2026, succeeding William Feehery, who will transition to an advisory role [1][3] - The company reaffirms its financial outlook for the full year 2025 as previously disclosed [4] Leadership Transition - Jon Resnick brings over 20 years of experience from IQVIA, where he held various leadership roles, including President of the U.S. and Canada regional business [2][3] - William Feehery has been credited with guiding Certara through its successful IPO and reinforcing its position as a global leader in biosimulation [4] Company Strategy and Vision - Resnick expressed enthusiasm about leading Certara, emphasizing the company's unique position in drug discovery and development through AI, data, and simulation technologies [3] - The company serves over 2,400 clients, including biopharmaceutical companies and regulatory agencies across 70 countries, highlighting its extensive market reach [5]

Core Viewpoint - Certara, Inc. will release its financial results for Q2 2025 on August 6, 2025, after market close, followed by a conference call at 5:00 PM ET to discuss the results [1]. Company Overview - Certara is a global leader in model-informed drug development, utilizing biosimulation software, technology, and services to enhance traditional drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Investor Information - Investors interested in the conference call must register online, with a recommendation to do so at least one day in advance [1]. - A live and archived webcast of the conference call will be available on the "Investors" section of Certara's website [2]. Contact Information - Investor Relations contact is David Deuchler from Gilmartin Group [4]. - Media contact is Alyssa Horowitz [4].